More on BioMarin's (BMRN) Q2 beat: Total revenue growth of 10.3% Y/Y. Revenue growth by product: Naglazyme, +11.1%; Kuvan, +17.9%; Firdapse, +13.9%; Aldurazyme, -19.7%. BMRN updates the Phase1/2 study of the PARP inihibtor BMN 673: As of yesterday the RECIST response rate had risen to 50% (nine out of 18 breast cancer patients). When data was presented at ASCO in June, the RECIST rate was 39%. BMRN also says the National Breast Cancer Coalition will partner on BMN 673's development. FY13 guidance unchanged: Revenue of $530-555M, Naglazyme and Kuvan revenue of $265-285M and $155-170M respectively. Shares off 1.44% AH. "Only reiterated guidance? Today's game is beat AND raise," Adam Feuerstein says, sarcastically.